Strong PD-L1 Expression Predicts Poor Response and de Novo Resistance to EGFR TKIs Among NSCLC Patients With EGFR Mutation.
This study retrospectively evaluated whether tumor expression of PD-L1 could predict the response of EGFR-mutated NSCLC to EGFR TKI therapy in 101 patients. Strong PD-L1 expression significantly decreased the objective response rate compared with weak or negative PD-L1 expression (35.7% vs 63.2% vs 67.3%; P = .002) and shortened progression-free survival (3.8 vs 6.0 vs […]
